natgillin/translations-raw huggingface dataset:
Benazepril and benazeprilat are extensively bound to plasma proteins (85– 90%), and in the tissues they are found mainly in the lung, liver and kidney.
Benazepril in benazeprilat se v veliki meri vežeta na plazemske beljakovine (85 - 90 %), v tkivih pa ju večinoma najdemo v pljučih, jetrih in ledvicah.
benazepril HCl 2.5 mg, spironolactone 20 mg benazepril HCl 5 mg, spironolactone 40 mg benazepril HCl 10 mg, spironolactone 80 mg
benazeprilijev HCl 2,5 mg, spironolakton 20 mg benazeprilijev HCl 5 mg, spironolakton 40 mg benazeprilijev HCl 10 mg, spironolakton 80 mg
benazepril HCl/spironolactone
benazeprilijev HCl/spironolakton
Benazepril hydrochloride (HCl) (benazeprilum HCl)
Benazeprilijev hidroklorid (HCl) (benazeprili HCl)
Benazepril hydrochloride is a prodrug hydrolysed in vivo to its active metabolite, benazeprilat.
Benazeprilijev klorid je predzdravilo, hidrolizirano in vivo v aktivni metabolit, benazeprilat.
Benazepril hydrochloride:
Benazeprilijev klorid
Benazeprilat is an ‘angiotensin converting enzyme (ACE) inhibitor’.
Benazeprilat je zaviralec encima angiotenzinske konvertaze (ACE).
Benazeprilat is an ‘angiotensin converting enzyme (ACE) inhibitor’.
Benazeprilat je „zaviralec encima angiotenzinske konvertaze (ACE)“.
BENCHMRK 1 and 2 Pooled
2 in več
BENCHMRK 1 and 2 Pooled 48 Weeks 96 Weeks
Združeni podatki študij BENCHMRK 1 in 2
BENCHMRK 1 and BENCHMRK 2 (multi-centre, randomised, double-blind, placebo-controlled trials) evaluated the safety and anti-retroviral activity of ISENTRESS 400 mg twice daily vs. placebo in a combination with optimized background therapy (OBT), in HIV-infected patients, 16 years or older, with documented resistance to at least 1 drug in each of 3 classes (NRTIs, NNRTIs, PIs) of anti- retroviral therapies.
Študiji BENCHMRK 1 in BENCHMRK 2 (multicentrični, randomizirani, dvojno slepi, s placebom nadzorovani preskušanji) sta vrednotili varnost in protiretrovirusno učinkovitost zdravila ISENTRESS v odmerku 400 mg dvakrat na dan pri z virusom HIV okuženih bolnikih, starih 16 let ali starejših, z dokazano odpornostjo na vsaj 1 zdravilo iz vsake od 3 skupin protiretrovirusnih zdravil (NRTI-ji, NNRTI-ji in PI-ji) v primerjavi s placebom v kombinaciji z optimiziranim osnovnim zdravljenjem (OBT - optimized background therapy).
Bend
Prepognite
BEND AND TEAR
PREPOGNITE IN ODTRGAJTE
Bend the blister unit along the line where indicated.
Enoto pretisnega omota prepognite vzdolž linije, kjer je označeno.
Bend the cap at a right angle until it snaps off.
Zaporko upognite pod pravim kotom, da se prelomi.
Bend the outer tube by 90° each way to ensure it is fully broken.
Upogibajte zunanjo cevko za 90° v obe smeri, da zagotovite, da se popolnoma odlomi.
Bend the patch back over itself.
Obliž zapognite nazaj.
Bend the patch in half so that the S-shaped break in the liner opens.
Obliž prepognite, tako da se razpoka v plasti v obliki črke S odpre.
Bend your head slightly forward.
Glavo nagnite nekoliko naprej.
Bend your head slightly forward;
Nagnite glavo nekoliko naprej.
Bendable straw for collection of the breath samples into the corresponding breath bags
Upogljiva slamica za zbiranje vzorcev izdihanega zraka v ustrezne dihalne vrečke
Bendable straw for collection of the breath samples into the corresponding breath bags
Upogljiva slamica za zbiranje vzorcev izdihanega zraka v ustrezne vrečke
Bendable straw for collection of the breath samples into the corresponding sample containers
Upogljiva slamica za zbiranje vzorcev izdihanega zraka v ustrezne epruvete
Bendable straw for collection of the breath samples into the corresponding sample containers
Upogljiva slamica za zbiranje vzorcev izdihanega zraka v ustrezne vsebnike
Bendamustine was dosed at 70 mg/m2 infused IV over 30 minutes on Cycle 1, Days 2 and 3, and on Cycles 2-6, Days 1 and 2 for up to 6 cycles.
Bolniki so 1. krog zdravljenja prejeli 70 mg/m2 bendamustina v obliki 30 minutne IV infuzije na dan 2 in 3, in 2.-6. krog zdravljenja na dan 1 in 2 do največ 6 krogov zdravljenja.
Beneficial effects of Riprazo on mortality and cardiovascular morbidity and target organ damage are currently unknown.
Ugodni vplivi zdravila Riprazo na umrljivost, kardiovaskularno obolevnost in prizadetost tarčnih organov trenutno niso znani.
benefit outweighs the risk.
tveganje.
Benefit was also shown for patients with genotype 1, 4, 5 and 6 with or without cirrhosis and/or for those who had received a liver transplant.
Koristno je bilo tudi za bolnike, okužene z virusom genotipa 1, 4, 5 in 6, s cirozo ali brez nje in/ali presajenimi jetri.
benefit-risk balance of the vaccine.
zvezi z razmerjem koristi in tveganj cepiva.
Benefit/risk assessment should include consideration of the greater frequency of concomitant disease or other medicinal product therapy in the elderly.
Pri oceni razmerja med koristmi in tveganjem je treba upoštevati, da je pri starejših bolnikih pogostnost sočasnih obolenj in sočasnega zdravljenja z drugimi zdravili večja.
Benefits of Defitelio were also seen in data from a patient registry in the United States, where patients with severe VOD following blood stem-cell transplantation who received Defitelio plus standard care had better outcomes than those given standard care alone, including a higher 100-day survival rate (39% versus 31%) and a higher proportion of patients whose VOD resolved (51% versus 29%).
Koristi zdravila Defitelio so pokazali tudi podatki registra bolnikov iz Združenih držav Amerike, kjer so imeli bolniki s hudo VOB po presaditvi krvotvornih matičnih celic, ki so prejeli zdravilo Defitelio v kombinaciji s standardno oskrbo, boljše izide kot bolniki, ki so prejeli samo standardno oskrbo, vključno z večjim 100-dnevnim deležem preživetja (39 % v primerjavi z 31 %) in večjim deležem bolnikov, pri katerih je VOB izzvenela (51 % v primerjavi z 29 %).
Benefits of using this medicine
Koristi uporabe tega zdravila
BeneFIX 1000 IU powder and solvent for solution for injection
BeneFIX 1.000 i.e. prašek in vehikel za raztopino za injiciranje
BeneFIX 1000 IU powder and solvent for solution for injection
BeneFIX 1000 i.e. prašek in vehikel za raztopino za injiciranje
BeneFIX 1000 IU powder for solution for injection
BeneFIX 1000 i.e. prašek in vehikel za raztopino za injiciranje
BeneFIX 2000 IU powder and solvent for solution for injection
BeneFIX 2.000 i.e. prašek in vehikel za raztopino za injiciranje
BeneFIX 2000 IU powder and solvent for solution for injection
BeneFIX 2000 i.e. prašek in vehikel za raztopino za injiciranje
BeneFIX 2000 IU powder for solution for injection
BeneFIX 2000 i.e. prašek in vehikel za raztopino za injiciranje
BeneFIX 250 IU powder and solvent for solution for injection
BeneFIX 250 i.e. prašek in vehikel za raztopino za injiciranje
BeneFIX 250 IU powder and solvent for solution for injection BeneFIX 500 IU powder and solvent for solution for injection BeneFIX 1000 IU powder and solvent for solution for injection BeneFIX 2000 IU powder and solvent for solution for injection BeneFIX 3000 IU powder and solvent for solution for injection
BeneFIX 250 i.e. prašek in vehikel za raztopino za injiciranje BeneFIX 500 i.e. prašek in vehikel za raztopino za injiciranje BeneFIX 1.000 i.e. prašek in vehikel za raztopino za injiciranje BeneFIX 2.000 i.e. prašek in vehikel za raztopino za injiciranje BeneFIX 3.000 i.e. prašek in vehikel za raztopino za injiciranje
BeneFIX 250 IU powder and solvent for solution for injection BeneFIX 500 IU powder and solvent for solution for injection BeneFIX 1000 IU powder and solvent for solution for injection BeneFIX 2000 IU powder and solvent for solution for injection BeneFIX 3000 IU powder and solvent for solution for injection Nonacog alfa (recombinant coagulation factor IX)
BeneFIX 250 i.e. prašek in vehikel za raztopino za injiciranje BeneFIX 500 i.e. prašek in vehikel za raztopino za injiciranje BeneFIX 1.000 i.e. prašek in vehikel za raztopino za injiciranje BeneFIX 2.000 i.e. prašek in vehikel za raztopino za injiciranje BeneFIX 3.000 i.e. prašek in vehikel za raztopino za injiciranje nonakog alfa (rekombinantni koagulacijski faktor IX)
BeneFIX 250 IU powder for solution for injection
BeneFIX 250 i.e. prašek za raztopino za injiciranje
BeneFIX 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU powder and solvent for solution for injection BeneFIX 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU of powder in a 10 mL vial (type 1 glass) with a stopper (chlorobutyl) and a flip-off seal (aluminium) and 5 mL of clear, colourless solvent in a prefilled syringe (type 1 glass) with a plunger stopper (bromobutyl), a tip-cap (bromobutyl) and a sterile vial adapter reconstitution device, a sterile infusion set, two alcohol swabs, a plaster, and a gauze pad.
BeneFIX 250 i.e., 500 i.e., 1.000 i.e., 2.000 i.e., 3.000 i.e. prašek in vehikel za raztopino za injiciranje BeneFIX 250 i.e., 500 i.e., 1.000 i.e., 2.000 i.e., 3.000 i.e. praška v 10-mililitrski viali (steklo tipa I) z zamaškom (iz klorobutila) in zaporko (iz aluminija) in 5 ml bistrega in brezbarvnega vehikla v napolnjeni injekcijski brizgi (steklo tipa I), zamašeni z batom (iz bromobutila), s koničastim pokrovčkom (iz bromobutila) in sterilnim rekonstitucijskim nastavkom za vialo, sterilen infuzijski sistem, dva alkoholna zloženca, obliž in blazinica iz gaze.
BeneFIX 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU powder and solvent for solution for injection Powder and solvent for solution for injection
BeneFIX 250 i.e., 500 i.e., 1.000 i.e., 2.000 i.e., 3.000 i.e. prašek in vehikel za raztopino za injiciranje prašek in vehikel za raztopino za injiciranje
BeneFIX 3000 IU powder and solvent for solution for injection
BeneFIX 3.000 i.e. prašek in vehikel za raztopino za injiciranje
BeneFIX 3000 IU powder and solvent for solution for injection Nonacog alfa (recombinant coagulation factor IX)
BeneFIX 3000 i.e. prašek in vehikel za raztopino za injiciranje nonakog alfa (rekombinantni koagulacijski faktor IX)
BeneFIX 3000 IU powder for solution for injection
BeneFIX 3000 i.e. prašek in vehikel za raztopino za injiciranje
BeneFIX 500 IU powder and solvent for solution for injection
BeneFIX 500 i.e. prašek in vehikel za raztopino za injiciranje
BeneFIX 500 IU powder for solution for injection
BeneFIX 500 i.e. prašek in vehikel za raztopino za injiciranje
BeneFIX has no influence on the ability to drive or use machines.
Zdravilo BeneFIX nima vpliva na sposobnost vožnje in upravljanja s stroji.
BeneFIX is administered by intravenous (IV) infusion after reconstitution of the powder for injection with the supplied solvent (a sodium chloride (salt) solution) in the pre-filled syringe.
Zdravilo BeneFIX se daje kot intravenska (i.v.) infuzija po rekonstituciji praška za injiciranje s priloženim vehiklom (raztopina natrijevega klorida (soli)) v napolnjeni injekcijski brizgi.
BeneFIX may be administered for long term prophylaxis against bleeding in patients with severe haemophilia B. In a clinical study for routine secondary prophylaxis the average dose for previously treated patients (PTP) was 40 IU/kg (range 13 to 78 IU/kg) at intervals of 3 to 4 days.
Zdravilo BeneFIX se lahko uporablja za dolgoročno profilakso krvavitev pri bolnikih s hudo hemofilijo B. V klinični študiji za rutinsko sekundarno profilakso je bil povprečni odmerek pri predhodno zdravljenih bolnikih (PTP – previously treated patients) 40 i.e./kg (razpon 13 do 78 i.e./kg) v presledkih 3 do 4 dni.
BeneFIX will be administered by intravenous infusion (IV) after reconstitution with sterile solvent for injection.
Zdravilo BeneFIX se daje kot intravenska infuzija (i.v.) po rekonstituciji s sterilnim vehiklom za injekcije.
Benepali 50 mg injection Etanercept Subcutaneous use <SC>
Benepali 50 mg injekcija etanercept subkutana uporaba <s.c.>
Benepali 50 mg solution for injection in pre-filled pen Etanercept
Benepali 50 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku etanercept
Benepali 50 mg solution for injection in pre-filled syringe Etanercept
Benepali 50 mg raztopina za injiciranje v napolnjeni injekcijski brizgi etanercept
Benepali can be taken with or without food or drink.
Zdravilo Benepali se lahko uporablja skupaj s hrano ali pijačo ali brez njiju.
Benepali contains the active substance etanercept and is a ‘biosimilar medicine’.
Zdravilo Benepali vsebuje zdravilno učinkovino etanercept in je „podobno biološko zdravilo“.
Benepali contains the active substance, etanercept.
Zdravilo Benepali vsebuje zdravilno učinkovino etanercept.
Benepali is administered by an injection under the skin (by subcutaneous injection).
Zdravilo Benepali se injicira pod kožo (subkutano injiciranje).
Benepali is administered by subcutaneous injection (see section 6.6).
Zdravilo Benepali se daje s subkutano injekcijo (glejte poglavje 6.6).
Benepali is available in packs containing 4 pre-filled pens and multipacks comprising 3 cartons, each containing 4 pre-filled pens.
Zdravilo Benepali je na voljo v pakiranjih, ki vsebujejo 4 napolnjene injekcijske peresnike, in v večodmernih pakiranjih, ki vsebuje 3 škatle, od katerih vsaka vsebuje po 4 napolnjene injekcijske peresnike.
Benepali is available in packs containing 4 pre-filled pens and multipacks containing 12 (3 packs of 4) pre-filled pens.
Zdravilo Benepali je na voljo v pakiranjih, ki vsebujejo 4 napolnjene injekcijske peresnike, in v večodmernih pakiranjih, ki vsebujejo 12 (3 pakiranja s po 4) napolnjenimi injekcijskimi peresniki.
Benepali is not for use in children, as Benepali does not have low-dose formulations.
Zdravilo Benepali ni namenjeno uporabi pri otrocih, saj ni na voljo v formulacijah z majhnim odmerkom.
Benepali is not for use in children.
Zdravilo Benepali ni primerno za uporabo pri otrocih
Benepali is not indicated for use in children and adolescents less than 18 years of age.
Zdravilo Benepali ni indicirano za uporabo pri otrocih in mladostnikih, starih do 18 let.
Benepali is not indicated for use in children and adolescents.
Zdravilo Benepali ni indicirano za uporabo pri otrocih in mladostnikih.
Benepali is not indicated for use in children less than 18 years of age.
Uporaba zdravila Benepali se ne priporoča pri otrocih, starih manj kot 18 let.
Benepali is not indicated in children.
Zdravilo Benepali ni indicirano pri otrocih.
Benepali is not recommended during pregnancy.
Uporaba zdravila Benepali med nosečnostjo ni priporočljiva.
Benepali is not recommended for the treatment of Wegener’s granulomatosis.
Zdravila Benepali ni priporočljivo uporabljati za zdravljenje Wegenerjeve granulomatoze.
Benepali is only available as a 50 mg pre-filled syringe or a 50 mg pre-filled pen which are unsuitable for use in children and adolescents.
Zdravilo Benepali je na voljo le v obliki 50 mg napolnjene injekcijske brizge ali 50 mg napolnjenega injekcijskega peresnika, ki za uporabo pri otrocih in mladostnikih nista primerna.
Benepali is only presented as a 50 mg pre-filled syringe and 50 mg pre-filled pen, while the recommended dose of etanercept for paediatric patients is 0.8 mg/kg given once weekly as lyophilized presentation.
Zdravilo Benepali je na voljo le kot 50 mg napolnjena injekcijska brizga in kot 50 mg napolnjen injekcijski peresnik, priporočeni odmerek etanercepta za pediatrične bolnike pa je 0,8 mg/kg enkrat na teden v liofilizirani obliki.
Benepali is supplied as a pre-filled syringe containing a clear, colourless or pale yellow solution for injection.
Zdravilo Benepali je na voljo v napolnjeni injekcijski brizgi, ki vsebuje bistro, brezbarvno do bledorumeno raztopino za injiciranje.
Benepali may be stored at temperatures up to a maximum of 25°C for a single period of up to four weeks; after which, it should not be refrigerated again.
Zdravilo Benepali se lahko shranjuje pri temperaturi do največ 25 °C za enkratno obdobje do štirih tednov, po katerem se ga ne sme več ohladiti.
Benepali must not be used in patients who have or are at risk of sepsis (when bacteria and toxins circulate in the blood and start to damage the organs), or in patients with infections.
Zdravila Benepali ne smejo uporabljati bolniki, ki imajo sepso ali pri katerih obstaja nevarnost sepse (ko bakterije in toksini krožijo v krvi in začnejo povzročati poškodbe organov), ali bolniki z okužbami.
Benepali should be discarded if not used within four weeks of removal from refrigeration.
Zdravilo Benepali zavrzite, če ga ne porabite v štirih tednih po odvzemu iz hladilnika.
Benepali treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non- radiographic axial spondyloarthritis, plaque psoriasis.
Zdravljenje z zdravilom Benepali lahko uvede in nadzoruje le zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem revmatoidnega artritisa, psoriatičnega artritisa, ankilozirajočega spondilitisa, radiografsko nezaznavnega aksialnega spondilartritisa in psoriaze v plakih.
Benepali was also compared with Enbrel in one main study involving 596 patients with moderate to severe rheumatoid arthritis despite treatment with methotrexate.
Zdravilo Benepali so z zdravilom Enbrel primerjali tudi v glavni študiji, ki je vključevala 596 bolnikov z zmernim do hudim revmatoidnim artritisom kljub zdravljenju z metotreksatom.
benign (non-cancerous) tumours and cysts (including those of the skin)
benigni (nerakavi) tumorji in ciste (vključno s kožnimi)
benign brain tumour (meningioma), bleeding in the head due to decreased blood platelet counts*,
benigni tumor možganov (meningioma) krvavitev v glavi zaradi zmanjšanega števila trombocitov
Benign breast neoplasm, breast fibroma, chronic lymphocytic leukaemia, endometrial neoplasm, female reproductive neoplasm, haemangioma, hepatic neoplasm malignant, leiomyoma, melanocytic naevus, multiple myeloma, neoplasm, parathyroid tumour benign
benigne novotvorbe dojk, fibrom dojke, kronična limfocitna levkemija, novotvorbe endometrija, novotvorbe ženskih genitalij, hemangiom, maligna novotvorba jeter , leiomiom, melanocitni nevus, multipli mielom, novotvorbe, benigen paratiroidni tumor
benign cysts a severe reversible brain condition which includes seizures, high blood pressure, headaches, tiredness, confusion, blindness or other vision problems.
nerakave ciste hudo reverzibilno stanje možganov s krči, visokim krvnim tlakom, glavoboli, utrujenostjo, zmedenestjo, slepoto in drugimi težavami z vidom.
Benign digestive symptoms, such as nausea, vomiting and abdominal pain, might be indicative of lactic acidosis development.
Razvoj laktacidoze lahko nakazujejo benigni prebavni simptomi, npr. navzea, bruhanje in bolečine v trebuhu.
Benign intracrania l hypertensi on
benigna intrakranialna hipertenzija
Benign intracranial hypertensio n
benigna intrakranialna hipertenzija
Benign intracranial hypertension
benigna intrakranialna hipertenzija
Benign intracranial hypertension
ekstrapiramidna motnja, sinkopa, benigna intrakranialna hipertenzija
Benign intracranial hypertension (or pseudotumor cerebri (PTC)) with papilledema; skin lesions, molluscoid pseudotumors, skin striae, skin fragility; joint hyperextension, leg pain, genu valgum, osteopenia, compression fracture and scoliosis have been reported with immediate-release cysteamine bitartrate (see section 4.4).
Pri uporabi cisteaminijevega bitartrata s takojšnjim sproščanjem so poročali o benigni intrakranialni hipertenziji (cerebralnem psevdotumorju) s papiloedemom; kožnih lezijah, moluskoidnih psevdotumorjih, kožnih strijah, nežni koži, ki se zlahka poškoduje; hiperekstenziji sklepov, bolečinah v spodnjih udih, deformaciji genu valgum, osteopeniji, kompresijski frakturi in skoliozi (glejte poglavje 4.4).
Benign intracranial hypertension, also called pseudotumor cerebri, has been reported with cysteamine use.
pri uporabi cisteamina so poročali o benigni intrakranialni hipertenziji, imenovani tudi cerebralni psevdotumor.
benign neoplasm
benigni tumor
benign neoplasm,
benigni tumor
Benign prostatic hyperplasia, breast disorder, breast pain
benigna hiperplazija prostate, motnje dojk, bolečina v dojkah
Benign prostatic hyperplasia, prostatitis, prostatic specific antigen increased
benigna hipertrofija prostate, prostatitis, zvišanje za prostato specifičnega antigena
Benign skin neoplasm
benigna kožna neoplazma
benign tumours
benigni tumorji
benign tumours;
benigni tumorji;
Benign, Malignant and Unspecified (including cysts and polyps)
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
Benlysta (given at doses of 1 and 10 mg per kg bodyweight) has been compared with placebo (a dummy treatment) in two main studies involving 1,693 adult patients with active SLE.
Zdravilo Benlysta (v odmerkih 1 in 10 mg na kilogram telesne mase) so primerjali s placebom (zdravilom brez zdravilne učinkovine) v dveh glavnih študijah, v katerih je sodelovalo 1 693 odraslih bolnikov z aktivnim sistemskim eritematoznim lupusom.
Benlysta 10 mg/kg (n=134)
Benlysta 10 mg/kg (n = 134)
Benlysta 10 mg/kg (n=305)
Benlysta 10 mg/kg (n = 305)
Benlysta 10 mg/kg* (n=273)
Benlysta 10 mg/kg* (n = 273)
Benlysta 10 mg/kg* (n=290)
Benlysta 10 mg/kg* (n = 290)
Benlysta 10 mg/kg* (n=563)
Benlysta 10 mg/kg* (n = 563)
Benlysta 120 mg powder for concentrate for solution for infusion
Benlysta 120 mg prašek za koncentrat za raztopino za infundiranje
Benlysta 120 mg powder for concentrate for solution for infusion Belimumab
Benlysta 120 mg prašek za koncentrat za raztopino za infundiranje belimumab
Benlysta 120 mg powder for concentrate for solution for infusion Benlysta 400 mg powder for concentrate for solution for infusion
Benlysta 120 mg prašek za koncentrat za raztopino za infundiranje Benlysta 400 mg prašek za koncentrat za raztopino za infundiranje
Benlysta 120 mg powder for concentrate for solution for infusion.
Benlysta 120 mg prašek za koncentrat za raztopino za infundiranje
Benlysta 400 mg powder for concentrate for solution for infusion
Benlysta 400 mg prašek za koncentrat za raztopino za infundiranje
Benlysta 400 mg powder for concentrate for solution for infusion Belimumab
Benlysta 400 mg prašek za koncentrat za raztopino za infundiranje belimumab
Benlysta 400 mg powder for concentrate for solution for infusion.
Benlysta 400 mg prašek za koncentrat za raztopino za infundiranje
Benlysta can cause a reaction to the infusion or an allergic (hypersensitivity) reaction.
Zdravilo Benlysta lahko povzroči reakcijo na infuzijo ali alergijsko (preobčutljivostno) reakcijo.
Benlysta can cause infections which can be of different types including chest infection, kidney infection, infection of nose and throat, bowel infection, etc.
Zdravilo Benlysta lahko povzroči različne vrste okužb, med drugim okužbo v prsnem košu, okužbo ledvic, okužbo nosu ali žrela, okužbo črevesa itn.
Benlysta contains belimumab (a monoclonal antibody).
Zdravilo Benlysta vsebuje belimumab (monoklonsko protitelo).
Benlysta contains less than 1 mmol sodium (23 mg) in each dose and therefore is essentially sodium-free.
Zdravilo Benlysta vsebuje manj kot 1 mmol (23 mg) natrija na odmerek in je tako v bistvu brez natrija.
Benlysta demonstrated improvement in fatigue compared with placebo measured by the FACIT-Fatigue scale in the pooled analysis.
V kumulativni analizi so pri zdravilu Benlysta v primerjavi s placebom ugotovili izboljšanje utrujenosti, merjene z lestvico FACIT-Fatigue.
Benlysta has a low sodium content
Zdravilo Benlysta vsebuje malo natrija
Benlysta has not been studied in the following patient groups, and is not recommended in:
Zdravilo Benlysta ni raziskano v naslednjih skupinah bolnikov, zato ga ni priporočljivo uporabljati pri bolnikih s:
Benlysta is a human IgG1 monoclonal antibody specific for soluble human B Lymphocyte Stimulator protein (BLyS, also referred to as BAFF and TNFSF13B).
Zdravilo Benlysta je človeško monoklonsko protitelo IgG1, specifično za topno humano B-limfocite stimulirajočo beljakovino (BLyS, ki jo označujejo tudi BAFF in TNFSF13B).
Benlysta is a medicine used to treat lupus (systemic lupus erythematosus, SLE) in adults (18 years of age and over) whose disease is still highly active despite standard treatment.
Zdravilo Benlysta je zdravilo za zdravljenje lupusa (sistemskega eritematoznega lupusa) pri odraslih bolnikih (starih 18 let in več), pri katerih je bolezen kljub standardnemu zdravljenju še vedno zelo aktivna.